13815-96-8

Upstream product

• 849669-08-5 [dodec-1-enyl(vinyl)phosphoryl]-benzene 
• 100-42-5 styrene 
• 824-72-6 P,P-dichlorophenylphosphine oxide 
• 1826-67-1 vinyl magnesium bromide 
• 644-97-3 Dichlorophenylphosphine 
• 26681-88-9 divinylphenylphosphine 
• 37912-68-8 Bis(2-bromethyl)-phenylphosphinoxid 

Downstream Products

• 52427-40-4 1-methyl-4-phenyl-4-oxotetrahydro-1,4-azaphosphorinane 
• 138420-98-1 7,7-Dimethyl-4-phenyl-8-oxa-1-aza-4-phospha-bicyclo[3.2.1]octane 4-oxide 
• 121071-45-2 C₁₆H₂₂NO₂P 
• 121071-45-2 C₁₆H₂₂NO₂P 
• 138442-61-2 C₁₅H₂₀NO₂P 
• 849669-08-5 [dodec-1-enyl(vinyl)phosphoryl]-benzene 
• 945459-99-4 1-oxo-1-phenyl-1λ5-phosphinane-4,4-dicarboxylic acid dibenzyl ester 
• 52427-43-7 4-phenyl-1,4-oxaphosphorinane 4-oxide 
• 53889-34-2 POC₆H₅((C₆H₅)2POCH₂CH₂)2 
• 52427-46-0 1-methyl-4-phenyl-[1,4]azaphosphinane 4-sulfide; hydrochloride 
• 945459-81-4 1-benzyl-4-phenyl-[1,4]azaphosphinane 4-oxide 
• 52427-45-9 1-methyl-4-phenyl-[1,4]azaphosphinane 4-sulfide 
• 52427-47-1 1-allyl-4-phenyl-[1,4]azaphosphinane 4-sulfide 
• 52427-44-8 1-methyl-4-phenyl-[1,4]azaphosphinane 

Relevant academic research and scientific papers

PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe

INHIBITORS OF TYROSINE KINASES AND USES THEREOF

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-rnediated diseases or conditions or tyrosine, kinase-dependent diseases or conditions are provided.

DESYMMETRISATION PROCESS

Provided is a process for producing a P-chiral phosphine compound using a cross-metathesis coupling reaction between a non-chiral phosphine and an olefin or an alkyne. The P-chiral phosphine compounds produced by this process are also disclosed.

Desymmetrization by direct cross-metathesis producing hitherto unreachable P-stereogenic phosphine oxides

Desymmetrization of prochiral di- and trialkenyl phosphine oxides by cross-metathesis with various olefinic partners allowed direct access to novel racemic P-stereogenic products featuring two or three different alkenyl groups. The excellent control of product selectivity and E/Z selectivity allowed the preparation of desymmetrized products in good yields from readily available precursors. These are the first examples of desymmetrization of prochiral substrates by direct cross-metathesis.